Yes, the path to displacing the standard of care is pretty clear...

Yes, the path to displacing the standard of care is pretty clear given the large gap between it and COVs test. This is in contrast to lung, breast, and colorectal cancers where the gold standards have much higher sensitivity and specificity, making commercialisation more difficult (not to mention they're all more cluttered). Another advantage here is the relatively fast path to market with the validation study due to commence soon. You'd have to think that the major diagnostic labs would be interested in coming on board at some point too given the high sensitivity and specificity and that it can be added to existing panels. I think this is a huge opportunity, and it's also ethical in the sense that such a significant difference with the standard of care will materially improve patient outcomes. There's a lot to like here and we have a busy year to come as we move towards FDA submissions in due course.